ERSPC, PLCO studies and critique of cochrane review 2013

Recent Results in Cancer Research

Volumn 202, Issue , 2014, Pages 59-63

  Schröder, Fritz H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER MORTALITY; CANCER SCREENING; COCHRANE LIBRARY; COLON CANCER; HUMAN; LUNG CANCER; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTOCOL COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; AGE DISTRIBUTION; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RESEARCH; PRACTICE GUIDELINE; RANDOMIZATION; RISK ASSESSMENT; TUMOR INVASION;

COLORECTAL NEOPLASMS; EUROPE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MASS SCREENING; MULTICENTER STUDIES AS TOPIC; OUTCOME ASSESSMENT (HEALTH CARE); OVARIAN NEOPLASMS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES;

EID: 84958545653     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-45195-9_7     Document Type: Review

References (8)

1. Ciatto S, Zappa M, Villers A, Paez A, Otto SJ, Auvinen A (2003) Contamination by opportunistic screening in the European randomized study of prostate cancer screening. BJU Int 92(2): 97-100
2. Grubb RL 3rd, Pinsky PF, Greenlee RT, Izmirlian G et al (2008) Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int 102(11): 1524-1530
3. Higgins JPT, Green S (eds) (2008) Cochrane handbook for systematic reviews of interventions. Wiley, New York
4. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA (2011) Cochrane bias methods group; cochrane statistical methods group. BMJ 18(343):d5928
5. Ilic D, Neuberger MM, Djulbegovic M, Dahm P (2013) Screening for prostate cancer. Cochrane Database Syst Rev 1:CD004720
6. Pinsky PF, Black A, Parnes HL, Grubb R, Crawford DE, Miller A, Reding D, Andriole G (2012) Prostate cancer specific survival in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. Cancer Epidemiol 36(6):e401-e406
7. Roobol MJ, Kerkhof M, Schröder FH, Cuzick J, Sasieni P, Hakama M, Stenman UH, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis L, Recker F, Berenguer A, Ruutu M, Kujala P, Bangma CH, Aus G, Tammela TL, Villers A, Rebillard X, Moss SM, de Koning HJ, Hugosson J, Auvinen A (2009) Prostate cancer mortality reduction by prostatespecific antigen-based screening adjusted for nonattendance and contamination in the European randomized study of screening for prostate cancer (ERSPC). Eur Urol 56(4): 584-591
8. Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ (2012) Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366: 981-990